360 Audit conducts specialist royalty audits across the pharmaceutical industry. Our team of multi-lingual auditors possess unparalleled knowledge in conducting audit programmes across the globe. It can take decades for pharmaceutical companies to get a drug through development and into the marketplace so it’s essential that they are being paid the correct royalties when it comes to licensing a drug, technology or intellectual property (IP) out to third parties.  

Ever complex licensing agreements, difficulties with translation issues and cultural barriers in the global pharmaceutical market mean that underpayments can be a common occurrence. Regular royalty audits ensure IP owners are being paid what they are owed. We can ensure you are receiving maximum commercial value through the exploitation of your IP by correlating payments with the licence agreements and identifying anomalies which are resulting in underpayments being made.

360 Audit ensures our clients are taken through the auditing process carefully, using it as an opportunity to advise them on how they can correct any system errors. We also ensure they are following the correct procedures by going through any weaknesses in their infrastructure which may be resulting in non-compliance with the licensing agreement.  

Most importantly, we recognise the relationship between licensor and licensee is of paramount importance and endeavour to ensure this is protected, irrespective of the findings of the audit.

  • North West entrepreneur shortlisted for national award

    NORTH WEST entrepreneur Henna Riaz has been shortlisted for a national business award.

    Ex-media lawyer Henna Riaz, founder of international royalty auditing business 360 Audit and business mana…

Our clients